Sarfaraz Niazi, PhD Discusses Market Projections For High-Concentration Adalimumab Biosimilars
Season 4, Episode 5, Feb 21, 2021, 12:00 PM
We sat down with Sarfaraz Niazi, PhD, an adjunct professor and biosimilar industry expert, to discuss the potential impact high-concentration adalimumab products could have on the US market.
To learn more about Celltrion's EU approval, click here.
To learn more about Alvotech’s high concentration adalimumab, click here.
To learn more about high-concentration citrate-free adalimumab products, click here.
To learn about the patent dance, click here.